In this portion of the conversation, Matthew Arango, PharmD, discusses how pharmacists approach monitoring for cardiotoxicity when patients receive HER2-directed therapies, beginning with the baseline cardiac assessments needed before treatment starts.
The panelists examined survey data revealing that approximately 40% of mothers with infants entering their first RSV season in 2025 expressed uncertainty or reluctance about administering the monoclonal antibody to their newborns.
In this segment, Matthew Arango, PharmD, walks through the essential counseling points pharmacists emphasize when patients begin HER2-diredcted therapy, helping them recognize what side effects are expected versus symptoms that require urgent attention.
The panelists examined the compelling new data showing a 30% reduction in RSV-associated hospitalizations for infants under 8 months and a striking 50% drop for those under 2 months, directly attributable to the introduction of maternal vaccination and monoclonal antibodies.
Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, breaks down the key distinctions between obstructive and nonobstructive hypertrophic cardiomyopathy (oHCM) and explains how cardiac myosin inhibitors target the underlying disease mechanism.
Icotrokinra, a first-in-class oral IL-23 receptor blocker, fills a long-standing gap in the treatment of moderate to severe plaque psoriasis.
Sharon Nachman, MD, division chief for pediatric infectious disease at Stony Brook Children's Hospital, shares her reaction to the court ruling blocking the scaled-back childhood vaccine schedule.
Pharmacists play a pivotal role in helping patients align healthy nutritional habits with consistent medication adherence to improve long-term chronic disease outcomes.
Olympic athlete Tabitha Peterson, PharmD, reveals how sports pharmacy helps athletes avoid antidoping risks, manage supplements safely, and stay competition-ready.
PharmD and Olympian Tabitha Peterson reveals how pharmacy analytics, teamwork, and constant learning fuel elite curling strategy and Olympic-level performance.
Despite persistent gaps in cardiovascular risk management, pharmacists are proving essential in improving LDL control, guiding statin use, and supporting evidence-based care across clinical settings.
Pharmacists have become central to titration, access, patient education, and logistics as GLP-1 use grows and cardiometabolic management evolves.
In this part of the discussion, Matthew Arango, PharmD, reviews what the DESTINY-Gastric studies have shown about trastuzumab deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca) in patients with progressive HER2-positive GEA, including response rates, survival benefits, and important safety considerations such as interstitial lung disease.
The panel examined the significant expansion of the Vaccines for Children (VFC) program to over 1000 birthing hospitals, now covering approximately 42% of US births and enabling broader access to respiratory syncytial virus immunizations for newborns.
In this section, Matthew Arango, PharmD, outlines how treatment for HER2-overexpressed gastroesophageal adenocarcinoma (GEA) has traditionally been approached and what distinguishes the major HER2-targeted agents used or emerging in this space.
The expert pharmacists examined the real-world administration errors that have emerged from having multiple respiratory syncytial virus vaccine options with different indications.
Experts debate tracking MS progression beyond EDSS, blending patient-reported symptoms, MRI metrics, and new ICD-10 coding for access.
Ronna Hauser breaks down findings showing that delayed manufacturer refunds under the Medicare Drug Price Negotiation Program are forcing retail pharmacies to minimize high-dollar drug inventory and dip into savings to stay afloat.
The experts express their concerns that current ACIP decisions and guidelines are not backed by "pure science."
Matthew Arango, PharmD, discusses the importance and challenges of HER2 testing in gastroesophageal adenocarcinoma and how biomarker results influence early treatment decisions and patient counseling.
Matthew Arango, PharmD, explains the basics of gastroesophageal adenocarcinoma (GEA), including its risk factors, typical patient profile, diagnostic process, and why cancers of the lower esophagus and stomach are treated as a single disease.
Niagen Bioscience’s NAD research, patents, and clinical trials, plus pharmacist-led supplement education to help consumers choose evidence-based vitamins and supplements.
Experts discuss guideline adoption, therapeutic advances, and team-based care.
To combat vaccine-related misinformation and disinformation, the speakers emphasize the importance of integrated education, community-led advocacy, and proactive outreach.
Explore how limited FDA enforcement impacts vitamins and supplements, as pharmacists push industry transparency with independent testing, COAs, and research-backed quality.
NCPA President Kristen Riddle recaps the organization's Multiple Locations Conference.
The expert pharmacists examined recent shifts in adult respiratory syncytial virus vaccination recommendations, clarifying that all adults 75 years or older should receive the vaccine, and that those aged 50 to 74 years with certain high-risk conditions are also eligible.
Experts weigh EDSS vs patient-reported symptoms in SPMS, urging composite endpoints, MRI insights, and smarter coding to improve therapy access.
The expert pharmacists examined the critical importance of timing in RSV immunization for pregnant individuals and infants, noting that patient conversations often fall at opposite ends of the spectrum, from eager acceptance to strong resistance.
Explore who drives REMS success—from FDA and manufacturers to pharmacists and patients—and how MS therapy routes shape safety, adherence, and workflow.
